2011
DOI: 10.1136/bmj.d5343
|View full text |Cite
|
Sign up to set email alerts
|

PVL positive Staphylococcus aureus skin infections

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
14
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(15 citation statements)
references
References 8 publications
1
14
0
Order By: Relevance
“…17 Repeated boils at body sites that are not typical for hidradenitis should be investigated with bacteriology swabs, looking particularly for Panton-Valentine leucocidin positive S aureus, which can cause recurrent boils that do not respond to treatment. 18 Pyogenic skin infections occurring in sites atypical for hidradenitis may indicate defects of immune function. If this is suspected, initial screening tests should include blood glucose; full blood count, differential, and film; IgA, IgM, IgG, and IgE; total complement; HIV screening; serum protein electrophoresis; and urine for Bence-Jones proteins.…”
Section: Recurrent Patternmentioning
confidence: 99%
“…17 Repeated boils at body sites that are not typical for hidradenitis should be investigated with bacteriology swabs, looking particularly for Panton-Valentine leucocidin positive S aureus, which can cause recurrent boils that do not respond to treatment. 18 Pyogenic skin infections occurring in sites atypical for hidradenitis may indicate defects of immune function. If this is suspected, initial screening tests should include blood glucose; full blood count, differential, and film; IgA, IgM, IgG, and IgE; total complement; HIV screening; serum protein electrophoresis; and urine for Bence-Jones proteins.…”
Section: Recurrent Patternmentioning
confidence: 99%
“…Of particular interest is that 3-carboxamide analogues, especially 2b , have shown bioactivity against various Gram-positive bacteria including clinically resistant strains such as MRSA, fluoroquinolone-resistant S. aureus , MDRSP, penicillin and erythromycin-resistant S. pneumonia and VRE as well as Gram-negative H. influenzae . Further optimisation, especially for overcoming high plasma-protein binding, is warranted but these compounds may be suitable for an evaluation for topical use [3132]. Significantly, these results suggest that a drug discovery approach based upon deconstruction–reconstruction inspired by suitable natural products with demonstrable biological activity provides a route for the rapid assembly of compound libraries, which, even if not fully optimized, provide a useful starting point for further elaboration.…”
Section: Resultsmentioning
confidence: 99%
“…The toxin was first described by Panton and Valentine in 1932. The PVL genes are carried by approximately <2% of both MRSA and MSSA according to the data published in 2005,6 and the majority of the isolates were PVL-producing MSSA (62%) 7. However, the data from the UK in 2010 demonstrated that 20% of the S. aureus isolated from skin or soft tissue infections was PVL positive 8…”
Section: Discussionmentioning
confidence: 99%